Ceragon網絡 CRNT 深 滬
已收盤 09-26 16:00:00 美东时间
2.37
+0.010
+0.42%
華盛通- 最 高2.395
- 今 開2.37
- 成交量 37.79万股
- 最 低 2.32
- 昨 收 2.36
- 總市值 2.11亿
- 52周最高 5.73
- 市盈率 靜 8.71
- 換手率 0.42%
- 52周最低 1.82
- 委 比 -67.02%
- 總股本 8892.97万
- 歷史最高 12.21
- 量 比 0.46
- 振 幅 3.18%
- 歷史最低 0.88
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Needham Reiterates Buy on Ceragon Networks, Maintains $3 Price Target
Needham analyst Ryan Koontz reiterates Ceragon Networks (NASDAQ:CRNT) with a Buy and maintains $3 price target.
09-18 18:49
Crane NXT to Participate in the 24th Annual D.A. Davidson Diversified Industrials & Services Conference
Crane NXT, Co. announced that its CEO Aaron Saak and CFO Christina Cristiano will participate in a fireside chat at the 24th Annual D.A. Davidson Diversified Industrials & Services Conference on September 18, 2025, at 1:50 p.m. CT. The event will be held virtually, and a live webcast will be available on Crane NXT’s investor relations website, with a replay accessible for one year. Crane NXT is an industrial technology company offering solutions ...
09-09 20:05
Smarter, Faster, and More Human: Cerence AI and Volkswagen Advance Partnership to Deliver Next-Gen In-Car Conversations
Volkswagen and Cerence AI have deepened their collaboration to enhance the in-car IDA assistant using Cerence Chat Pro, enabling more natural and complex conversations. Features include multi-turn dialogue and a broader knowledge base, improving user experience and delivering added value post-purchase. The upgrade is available across various Volkswagen brands, supporting intuitive interactions that feel more human-like, thus elevating the driving...
08-25 12:00
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals announced that the FDA granted Orphan Drug Designation (ODD) for atumelnant, a novel once-daily oral ACTH receptor antagonist for treating classic congenital adrenal hyperplasia (CAH). Atumelnant is the first small molecule ACTH receptor antagonist in clinical development. The company highlighted the significant unmet need for CAH patients and aims to demonstrate the ability to restore normal adrenal androgen levels and ...
08-21 12:45
Ceragon Networks Secures $8 Million Network Modernization Project in EMEA
Ceragon Networks ( ($CRNT) ) has issued an announcement. On August 13, 2025, Ce...
08-13 20:28
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported Q2 2025 financial results, highlighting progress toward its acromegaly drug PALSONIFY™ with an FDA PDUFA date of Sept 25, 2025. The company advanced multiple clinical programs, including atumelnant for CAH, and presented data at major medical meetings. Cash reserves of $1.2B are expected to support operations into 2029.
08-07 20:05
Ceragon Networks shares are trading lower after the company reported worse-than-expected Q2 financial results.
Ceragon Networks shares are trading lower after the company reported worse-than...
08-06 20:42
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
